Business Development

What are we looking for?

Ferring's primary business development objective is to complement the company's portfolio. A key strategic objective is to grow our business in the United States and Japan. In particular, the company is interested in late-stage products (phase IIb and onwards), as well as products already marketed globally and regionally.

Areas of interest


Gastroenterology

    • Over the next few years Ferring will be looking for products to supplement PENTASA® and its R&D gastro pipeline for the treatment of Crohn's disease and ulcerative colitis.
    • Long term, Ferring is interested in new treatment options for inflammatory bowel diseases and other lower gastro-intestinal conditions.
    • Long term, Ferring is looking to develop the next generation of the GLYPRESSIN®-inspired treatments.


Reproductive health

Ferring Pharmaceuticals is committed to obstetrics and gynaecology where its existing products concentrate on utilising the body's natural processes to help couples conceive and to ensure a successful pregnancy.

By being able to offer new and innovative products in these areas, it is Ferring's vision to provide the best treatments to aid every stage of the reproductive cycle. 

Furthermore Ferring aims to help women to overcome and live with diseases of the Reproductive System.


Urology

Ferring is interested in innovative products to supplement its existing portfolio of drugs in the Urology and Uro-Oncology area.

We are also receptive to considering opportunities targeting specialty physician segments which may be outside of our core therapeutic areas.

Latest projects

Who to contact

Preclinical Research Programmes

The Director of Business Development for the Ferring Research Institute is responsible for reviewing peptide and protein-based preclinical research programmes and technologies that have potential utility in Ferring’s core therapeutic areas.

Preclinical Research Programmes

Adrienne Day
Senior Director, Business Development Research
Phone: +1 858 657 1511 (USA)
email: adrienne.day@ferring.com

Ferring Research Institute

Early Stage Clinical Compounds and Drug Delivery Systems

Ferring's Senior Vice President, Global Project and Portfolio Management, leads the evaluation of R&D opportunities in pre-phase IIB development and consults with other relevant Ferring divisions. In addition, he leads the out-licensing process of Ferring's early-stage compounds.

Early Stage Clinical Compounds and Drug Delivery Systems

Alan S. Harris
Senior Vice President, Global Project and Portfolio Management
Phone: +41 58 301 00 00 (Switzerland)
email: alan.harris@ferring.com

and

Tony Mason
Director, Global Projects Management
Phone: +41 58 301 00 00 (Switzerland)
email: tony.mason@ferring.com

Test Test
Late Stage and Merger & Acquisitions

Ferring's Business Development team focuses on late stage compounds that are ready to go to phase IIb as well as on product and company acquisitions.

USA 
Bipin Dalmia
Vice President, US Business Development
Phone: +1 973 796 1600 (US)
email: bipin.dalmia@ferring.com

Reproductive Health, New Therapeutic Areas and/or Europe
Valentine France-Lanord
Senior Director Business Development 
Phone: +41 58 301 00 00 (Switzerland)
email: valentine.france-lanord@ferring.com

Gastro, Endocrinology, Urology and/or Asia, Middle East, Latin America
David Benathan

Senior Director, Global Business Development
Phone: +41 58 301 00 00 (Switzerland)
email: david.benathan@ferring.com

Headquarters

FERRING INTERNATIONAL CENTER S.A.
CH. DE LA VERGOGNAUSAZ 50
1162 SAINT-PREX
SWITZERLAND

TEL:  +41 58 301 00 00
FAX: +41 58 301 00 10

CONTACT

global locator